Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

INSIGHT-IBD Pragmatic Study

28 de octubre de 2026 actualizado por: Specialty Networks Research.

INSIGHT-IBD Pragmatic Study: Investigation of Mirikizumab in Real World Settings for Mirikizumab

The goal of this study is to evaluate the real-world effectiveness of treatments for inflammatory bowel disease (IBD) within routine clinical practice.

The study population includes adult patients (≥21 years) with ulcerative colitis (UC) or Crohn's disease (CD) receiving care in community gastroenterology practices in the United States.

The main questions it aims to answer are:

  • Does treatment with mirikizumab reduce the proportion of patients requiring an increase in IBD disease management (e.g., unplanned visits, dose escalation, therapy switch, emergency department visits, or hospitalization)?
  • Does treatment with mirikizumab improve clinical outcomes, including disease activity, clinical remission, and patient-reported outcomes, compared to standard biologic therapy?
  • Researchers will compare patients treated with mirikizumab within the IBD Clinical Care Pathway versus patients receiving standard biologic therapies to see if mirikizumab leads to improved disease control and reduced healthcare utilization.

Participants will:

  • Receive either mirikizumab or standard biologic therapy as part of routine clinical care
  • Attend follow-up visits at approximately 3, 6, 12, and 18 months
  • Have clinical data collected from electronic health records and healthcare utilization sources
  • Complete patient-reported outcome questionnaires assessing symptoms, quality of life, and daily functioning
  • Undergo routine laboratory tests and clinical assessments as part of standard care

Descripción general del estudio

Estado

Inscripción por invitación

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

400

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Arizona
      • Sun City, Arizona, Estados Unidos, 85351
        • Arizona Digestive Health
      • Tucson, Arizona, Estados Unidos, 85704
        • AZ Digestive Health-Tucson
    • Illinois
      • Glenview, Illinois, Estados Unidos, 60005
        • GI Alliance of Illinois
      • Gurnee, Illinois, Estados Unidos, 60031
        • Lake Shore Gastro-Gurnee Research
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46237
        • Indianapolis Gastroenterology & Hepatology
    • New York
      • Rochester, New York, Estados Unidos, 14618
        • Gastroenterology Group of Rochester
    • Texas
      • Cedar Park, Texas, Estados Unidos, 78613
        • Texas Digestive Disease Consultants
      • Fort Worth, Texas, Estados Unidos, 76104
        • Texas Digestive Disease Consultants
      • Houston, Texas, Estados Unidos, 77024
        • Digestive Health Associates
      • Plano, Texas, Estados Unidos, 75093
        • Texas Digestive Disease Consultants: Plano
      • San Antonio, Texas, Estados Unidos, 78215
        • Texas Digestive Disease Consultants: San Antonio
      • San Marcos, Texas, Estados Unidos, 78666
        • Texas Digestive Disease Consultants: San Marcos
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23229
        • GI Alliance Richmond

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

21 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age ≥21 years at the time of enrollment
  • Confirmed diagnosis of ulcerative colitis (UC) or Crohn's disease (CD)
  • Eligible for treatment with biologic therapy for IBD, as per the IBD Clinical Care Pathway
  • No prior exposure to mirikizumab and no contraindications to mirikizumab
  • Ability to provide informed consent
  • Willingness to comply with study procedures and follow-up requirements

Exclusion Criteria:

  • Prior exposure to IL-23p19 antagonists (e.g., mirikizumab, risankizumab, guselkumab)
  • Prior exposure to small molecule targeted therapies for IBD (e.g., JAK inhibitors or S1P receptor modulators)
  • Participation in an interventional clinical trial within 90 days prior to enrollment
  • History of extensive colorectal resection, including:
  • Total proctocolectomy (for UC), or
  • Surgical removal of two or more intestinal segments (for CD)
  • Any condition that, in the investigator's judgment, may compromise patient safety, data integrity, or ability to participate in the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Mirikizumab Clinical Care Pathway

Participants receive mirikizumab as part of the IBD Clinical Care Pathway in routine clinical practice. Dosing and administration follow the approved prescribing information for ulcerative colitis or Crohn's disease, with treatment and monitoring per standard of care.

Mirikizumab administered according to approved dosing regimens for ulcerative colitis and Crohn's disease.

Comparador activo: Standard Biologic Therapy Clinical Care Pathway

Participants receive standard biologic therapies for IBD as part of the IBD Clinical Care Pathway according to physician discretion and routine clinical practice. Therapies may include anti-TNF agents, anti-integrins, IL-12/23 antagonists, or IL-23p19 antagonists.

Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.

Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.

Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.

Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of Patients Requiring an Increase in IBD Disease Management
Periodo de tiempo: Up to 18 months following initiation of therapy

The proportion of patients requiring an increase in inflammatory bowel disease (IBD) disease management, defined as a composite of treatment and healthcare resource use, while receiving index therapy.

Up to 18 months following initiation of therapy

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Disease Activity Measured by Crohn's Disease PRO2 Scores
Periodo de tiempo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in disease activity assessed using validated patient-reported outcome measures:

Crohn's Disease Patient-Reported Outcome 2 (CD PRO2), composed of:

Abdominal pain score (range 0-3) Stool frequency (number of bowel movements per day; higher values indicate worse disease activity)

Changes in PRO2 component scores and composite disease activity will be evaluated over time, with decreases from baseline indicating improvement in disease activity.

Baseline, 6 months, 12 months, and 18 months
Change in Disease Activity Measured by Ulcerative Colitis PRO2 Scores
Periodo de tiempo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in disease activity assessed using validated patient-reported outcome measures:

Ulcerative Colitis Patient-Reported Outcome 2 (UC PRO2), composed of:

Stool frequency score (range 0-3) Rectal bleeding score (range 0-3) Total possible combined score range: 0-6, with higher scores indicating worse disease activity

Changes in PRO2 component scores and composite disease activity will be evaluated over time, with decreases from baseline indicating improvement in disease activity.

Baseline, 6 months, 12 months, and 18 months
Proportion of Participants Achieving Endoscopic Remission Measured by Simple Endoscopic Score for Crohn's Disease (SES-CD)
Periodo de tiempo: Up to 18 months (as available from routine clinical care)

Proportion of participants achieving endoscopic remission assessed using validated endoscopic scoring system:

Simple Endoscopic Score for Crohn's Disease (SES-CD) (range 0-56), where lower scores indicate less endoscopic disease activity and endoscopic remission is defined as a score ≤2

Endoscopic findings are collected as part of routine clinical care, when available.

Up to 18 months (as available from routine clinical care)
Proportion of Participants Achieving Endoscopic Remission Measured by Modified Baron Score.
Periodo de tiempo: Up to 18 months (as available from routine clinical care)

Proportion of participants achieving endoscopic remission assessed using validated endoscopic scoring systems:

Modified Baron Score (ulcerative colitis) (range 0-4), where lower scores indicate less mucosal inflammation and endoscopic remission is defined as a score of 0 (normal mucosa with no visible inflammation)

Endoscopic findings are collected as part of routine clinical care, when available.

Up to 18 months (as available from routine clinical care)
Treatment Persistence
Periodo de tiempo: Up to 18 months

Duration of time from treatment initiation to discontinuation of index therapy for any reason, including continued use at pre-specified timepoints.

Up to 18 months
Proportion of Patients with Dose Escalation
Periodo de tiempo: Up to 18 months

Proportion of patients who discontinue index therapy and/or initiate a subsequent IBD therapy during the study period.

Up to 18 months
Time to Next Treatment
Periodo de tiempo: Up to 18 months

Time from initiation of index therapy to initiation of a subsequent therapy or discontinuation of index therapy.

Up to 18 months
Concomitant Medication Use
Periodo de tiempo: Baseline through 18 months

Proportion of patients receiving concomitant corticosteroids, immunomodulators, or aminosalicylates at baseline and during follow-up, including initiation and discontinuation patterns.

Baseline through 18 months
Corticosteroid-Free Time
Periodo de tiempo: Up to 18 months

Duration of time patients remain free from corticosteroid use while receiving index therapy.

Up to 18 months
Healthcare Resource Utilization
Periodo de tiempo: Up to 18 months

Frequency and rate of IBD-related healthcare utilization

Up to 18 months
Change in Patient-Reported Outcomes Measured by SIBDQ
Periodo de tiempo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in patient-reported outcomes assessed using validated instrument:

Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (range 10-70), where higher scores indicate better health-related quality of life

Changes in scores over time will be evaluated to assess symptom burden, quality of life, and functional outcomes.

Baseline, 6 months, 12 months, and 18 months
Change in Patient-Reported Outcomes Measured by UNRS
Periodo de tiempo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in patient-reported outcomes assessed using validated instrument:

Bowel Urgency Numeric Rating Scale (UNRS) (range 0-10), where higher scores indicate worse bowel urgency

Changes in score over time will be evaluated to assess symptom burden, quality of life, and functional outcomes.

Baseline, 6 months, 12 months, and 18 months
Change in Patient-Reported Outcomes Measured by PROMIS Global Health
Periodo de tiempo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in patient-reported outcomes assessed using validated instrument:

PROMIS Global Health (PROMIS-GH) (T-score standardized, mean 50), where higher scores indicate better overall health status

Changes in score over time will be evaluated to assess symptom burden, quality of life, and functional outcomes.

Baseline, 6 months, 12 months, and 18 months
Change in Patient-Reported Outcomes Measured by SAA
Periodo de tiempo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in patient-reported outcomes assessed using validated instrument:

Sexual Activity Avoidance (SAA), where higher scores indicate greater avoidance of sexual activity

Changes in scores over time will be evaluated to assess symptom burden, quality of life, and functional outcomes.

Baseline, 6 months, 12 months, and 18 months
Change in Patient-Reported Outcomes Measured by WPAI:SHP
Periodo de tiempo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in patient-reported outcomes assessed using validated instrumens:

Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) (0-100%), where higher percentages indicate greater impairment

Changes in score over time will be evaluated to assess symptom burden, quality of life, and functional outcomes.

Baseline, 6 months, 12 months, and 18 months
Proportion of Participants Achieving Clinical Remission Based on Ulcerative Colitis PRO2.
Periodo de tiempo: Baseline, 6 months, 12 months, and 18 months

Proportion of participants achieving clinical remission based on validated patient-reported outcome measures:

Ulcerative Colitis Patient-Reported Outcome 2 (UC PRO2), composed of:

Stool frequency score (range 0-3) Rectal bleeding score (range 0-3) Lower scores indicate less disease activity; clinical remission is defined as rectal bleeding score = 0 and stool frequency score ≤1

These thresholds represent minimal or no symptoms consistent with clinical remission.

Baseline, 6 months, 12 months, and 18 months
Proportion of Participants Achieving Clinical Remission Based on Crohn's Disease PRO2.
Periodo de tiempo: Baseline, 6 months, 12 months, and 18 months

Proportion of participants achieving clinical remission based on validated patient-reported outcome measures: Crohn's Disease Patient-Reported Outcome 2 (UC PRO2), composed of: Stool frequency score (range 0-3) Rectal bleeding score (range 0-3) Lower scores indicate less disease activity; clinical remission is defined as rectal bleeding score = 0 and stool frequency score ≤1 These thresholds represent minimal or no symptoms consistent with clinical remission.

Baseline, 6 months, 12 months, and 18 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Casey Chapman, MD, GIA
  • Investigador principal: Nicholas Lazarou, MPH, MBA, Cardinal Health

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

12 de agosto de 2026

Finalización primaria (Estimado)

1 de junio de 2028

Finalización del estudio (Estimado)

1 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

18 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

29 de junio de 2026

Publicado por primera vez (Actual)

7 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 103899

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

This study does not plan to share Individual Participant Data (IPD)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .